ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
With reference to the captioned matter, please find enclosed herewith the transcript of the Conference Call held on 11th November, 2022. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
With reference to the captioned subject, please find enclosed herewith the intimation dated 16th November, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s).
Alembic Pharma gets USFDA nod for generic cancer treatment medication
Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market Cyclophosphamide capsules, used in the treatment of different kinds of cancers, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Hikma Pharmaceuticals USA Inc product, Alembic Pharmaceuticals said in a statement. Cyclophosphamide capsules is an alkylating drug indicated for the treatment of malignant disease and minimal change nephrotic syndrome in pediatric patients. According to IQVIA, cyclophosphamide capsules, 25 mg and 50 mg, have an estimated market size of USD 8 million in the US for twelve months ending Sep 2022. Shares of the drug firm were trading 1.32 per cent down at Rs 630.35 apiece on the BSE. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Cyclophosphamide Capsules, 25 mg and 50 mg. Please find enclosed herewith our press release. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to the captioned matter, this is to inform the exchange that the audio recording has been hosted on the website of the Company and can be accessed at https://alembicpharmaceuticals.com/quarterly-results/ ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
With reference to the captioned matter, we would like to inform that the 12th Annual General Meeting of the Company was held on 11th November, 2022 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). Please find enclosed herewith: a) Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. b) Scrutinizers' Report on E-voting as per the provisions of Section 108 of the Companies Act, 2013 read with Companies (Management and Administration), Rules, 2014. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholder Meeting / Postal Ballot-Outcome of AGM
With reference to the captioned matter, we would like to inform that the 12th Annual General Meeting of the Company was held on 11th November, 2022 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). Please find enclosed herewith: a) Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. b) Scrutinizers' Report on E-voting as per the provisions of Section 108 of the Companies Act, 2013 read with Companies (Management and Administration), Rules, 2014.
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Proceedings Of The 12Th Annual General Meeting Held On 11Th November, 2022
In accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith proceedings of the 12th Annual General Meeting of the Company held on 11th November, 2022. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholder Meeting / Postal Ballot-Outcome of AGM
In accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith proceedings of the 12th Annual General Meeting of the Company held on 11th November, 2022.